Telitacicept Improves Clinical Response in Active SLE
In a 52-week trial, telitacicept showed a higher clinical response rate in patients with active systemic lupus erythematosus (SLE) compared to placebo.
Patients treated with telitacicept had significant improvements in disease activity scores, reflecting better control of lupus manifestations such as rash, arthritis, and serologic activity.
However, the treatment was linked to increased rates of upper respiratory infections, decreased immunoglobulin levels, and injection-site reactions.
The trial demonstrated that telitacicept’s mechanism—targeting both BAFF and APRIL pathways—effectively suppresses B-cell overactivation, a key driver of autoimmunity in SLE.
The study highlights the need for careful monitoring due to the increased risk of infections and other adverse effects.
Author's summary: Telitacicept improves SLE response rates.
More News
- We cannot sit back to AI
- Government Shutdown Deepens: Senate Vote Fails For 13th Time As Food, Pay Crisis Loom
- Cal/OSHA Issues Late-Season Heat Advisory for Southern California -- Occupational Health & Safety
- Saints hand keys to rookie Tyler Shough after brutal 1-7 start
- Kieran McKenna Linked with Celtic Job
- Scott Woods band returning for Christmas Hoedown | DrumhellerMail
- Building a stable ‘abode of thought’: Kant’s rules for virtuous thinking
- Bitcoin Miner TeraWulf (WULF) Stock Jumps 25% On AI News
- Greater Victoria Harbour Authority cancels shore power plan for Ogden Point
- Liverpool vs. Crystal Palace: Carabao Cup team news & TV info